Form 8-K - Current report:
SEC Accession No. 0001193125-23-241316
Filing Date
2023-09-25
Accepted
2023-09-25 16:02:02
Documents
13
Period of Report
2023-09-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d519116d8k.htm   iXBRL 8-K 37174
2 EX-10.1 d519116dex101.htm EX-10.1 51548
  Complete submission text file 0001193125-23-241316.txt   233007

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA agle-20230919.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20230919_lab.xml EX-101.LAB 18758
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20230919_pre.xml EX-101.PRE 11707
7 EXTRACTED XBRL INSTANCE DOCUMENT d519116d8k_htm.xml XML 3530
Mailing Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231275841
SIC: 2834 Pharmaceutical Preparations